Probi AB

PROB

SE0001280355

Pharmaceuticals

Delayed Nasdaq Stockholm Other stock markets 05:38:24 2024-04-24 am EDT			5-day change	1st Jan Change
205 ^SEK	+0.49%		-6.82%	+0.99%

Apr. 23	Transcript : Probi AB, Q1 2024 Earnings Call, Apr 23, 2024
Apr. 23	Probi AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Rights Issue: 1 new share @ 264 SEK for 4 existing shares

October 04, 2016

Latest news about Probi AB

Transcript : Probi AB, Q1 2024 Earnings Call, Apr 23, 2024	Apr. 23
Probi AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Probi AB Strengthens Its Brand Position and Expands in the Nordics	Mar. 13	CI
Transcript : Probi AB, Q4 2023 Earnings Call, Jan 26, 2024	Jan. 26
Probi AB Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 26	CI
Probi AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Jan. 26	CI
Probi AB Proposes Dividend for the Fiscal Year 2023	Jan. 26	CI
Transcript : Probi AB, Q3 2023 Earnings Call, Oct 24, 2023	23-10-24
Probi AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-24	CI
Thunderful Group Names New CFO	23-10-23	MT
Sweden’s Probi Names New CFO	23-10-20	MT
Probi AB Appoints Per Lindblad as New CFO, Effective from 1st of November, 2023	23-10-20	CI
Probi Launches Two New Concepts Together with Clasado Biosciences at Supply Side West	23-10-19	CI
Probi Sensia to Be Launched by Probi at SupplySide West in October 2023	23-10-02	CI
New Clinical Study Shows Clear Benefits of Probi's Probiotics for Metabolic Health	23-07-27	CI
Transcript : Probi AB, Q2 2023 Earnings Call, Jul 18, 2023	23-07-18
Probi AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-18	CI
Probiotics Group Probi's Finance Chief to Depart	23-07-06	MT
Probi AB Announces Resignation of Henrik Lundkvist as Chief Financial Officer	23-07-05	CI
Sweden’s Probi, UK’s Clasado Biosciences to Collaborate on Synbiotic Product Development	23-06-08	MT
Probi AB Takes over All Distribution of Blis K12 and Blis M18 in North America	23-05-22	CI
Probi AB Approves Dividend for the Financial Year 2022	23-05-04	CI
Transcript : Probi AB, Q1 2023 Earnings Call, Apr 26, 2023	23-04-26
Probi AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Probi AB Appoints Anita Johansen as Chief Executive Officer, Effective April 1, 2023	23-03-30	CI

Probi AB is a Sweden-based company engaged in the probiotics research and development. The Companyâs activities are divided into two business areas: Functional Foods, which focuses on the probiotics application in food in partnership with food companies; and Consumer Healthcares, which develops, commercializes and sells Probi probiotics in collaboration with a range of entities, such as pharmaceutical companies and firms related to the production of probiotics and self-care goods. Its brands portfolio comprises two trademarks: Probi Digestis and Probi Defendum. The Company's partners include Danone, Skanemejerier, NextFoods, Sanum Polska, Heinz, Kraft Foods, and Institut Rosell, among others. The Company is a parent of Probi Food AB and Probi Feed AB.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Probi AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PROBI AB	+0.99%	215M
ELI LILLY AND COMPANY	+27.92%	672B
NOVO NORDISK A/S	+26.92%	570B
JOHNSON & JOHNSON	-4.59%	360B
MERCK & CO., INC.	+16.38%	321B
ABBVIE INC.	+9.39%	300B
ASTRAZENECA PLC	+7.28%	217B
NOVARTIS AG	+6.23%	199B
ROCHE HOLDING AG	-9.08%	204B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals

Probi AB

Equities

PROB

SE0001280355

Pharmaceuticals

Rights Issue: 1 new share @ 264 SEK for 4 existing shares

Latest news about Probi AB

Chart Probi AB

Company Profile

Income Statement Evolution

Ratings for Probi AB

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals